(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
4 February 2010 (04.02.2010)

PCT

(10) International Publication Number
WO 2010/012780 A1

(51) **International Patent Classification**:
A61K 39/12 (2006.01) *A61P 35/00* (2006.01)

(21) **International Application Number**:
PCT/EP2009/059820

(22) **International Filing Date**:
29 July 2009 (29.07.2009)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:

61/085,101	31 July 2008 (31.07.2008)	US
61/176,561	8 May 2009 (08.05.2009)	US

(71) **Applicant** *(for all designated States except US)*: **GLAXOSMITHKLINE BIOLOGICALS S.A.** [BE/BE]; Rue de l'Institut 89, B-1330 Rixensart (BE).

(72) **Inventors; and**

(75) **Inventors/Applicants** *(for US only)*: **DESCAMPS, Dominique** [BE/BE]; GlaxoSmithKline Biologicals S.A., Rue de l'Institut 89, B-1330 Rixensart (BE). **GIANNINI, Sandra** [US/BE]; GlaxoSmithKline Biologicals S.A., Rue de l'Institut 89, B-1330 Rixensart (BE). **LECRENIER, Nicolas** [BE/BE]; GlaxoSmithKline Biologicals S.A., Rue de l'Institiut 89, B-1330 Rixensart (BE). **STEPHENNE, Jean** [BE/BE]; GlaxoSmithKline Biologicals S.A., Rue de l'Institut 89, B-1330 Rixensart (BE). **WETTENDORFF, Martine Anne Cecile** [BE/BE]; GlaxoSmithKline Biologicals S.A., Parc de la Noire Epine, Rue Fleming 20, B-1330 Wavre (BE).

(74) **Agents**: **PRIVETT, Kathryn Louise** et al.; GlaxoSmithKline, Corporate Intellectual Property (CN925.1), 980 Great West Road, Brentford Middlesex TW8 9GS (GB).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

WO 2010/012780 A1

(54) **Title**: VACCINE AGAINST HPV

(57) **Abstract**: The use of HPV 16 and HPV 18 virus like particles (VLPs) together with a pharmaceutically acceptable excipient, in a vaccine for the prevention of human papillomavirus related disease or infection, wherein the vaccine is formulated for administration according to a two dose regimen consisting of a first dose and a second dose.